A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 378 participants.

Also called NCT03422653

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 378 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03422653
Other papers using this trial's data
  • A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus The New England journal of medicine, 2020-01-16 DOI, PubMed 31702883

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03422653. Randomized; double masking; primary purpose treatment. Start 2018-02-20 (actual); primary completion 2019-04-06 (actual). Results posted on 2022-04-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
Condition
Uremic Pruritus
Intervention (Drug)
CR845 0.5 mcg/kg
Intervention (Drug)
Placebo
Lead sponsor
Cara Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03422653
Content hash
39fcb2da7d71bd5a5bc0a4279d8084efb6800eec8d5180faa7b113138d0dfa03